Loading...

Fran Aweeka, PharmD

Title(s)Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
Phone415-476-0339
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Southern CaliforniaB.S. Biological Sciences1981
    University of California, San FranciscoPharm.D.1985 Pharmacy
    University of California, San FranciscoPHA Primary Practice Residency1986 Pharmacy
    University of California, San FranciscoPharmacology Fellowship1988

    Collapse Research 
    Collapse Research Activities and Funding
    Pharmacodynamics of Antimalarial Chemoprevention
    NIH/NIAID R01AI117001Feb 10, 2015 - Jan 31, 2020
    Role: Principal Investigator
    Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda
    NIH R01HD068174Dec 23, 2010 - Aug 31, 2021
    Role: Principal Investigator
    UCSF-Gladstone Center for AIDS Research
    NIH/NIAID P30AI027763Sep 30, 1988 - Aug 31, 2022
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Scarsi KK, Cramer YS, Rosenkranz SL, Aweeka F, Berzins B, Coombs RW, Coughlin K, Moran LE, Zorrilla CD, Akelo V, Aziz M, Friedman RK, Gingrich D, Swaminathan S, Godfrey C, Cohn SE. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. Lancet HIV. 2019 Sep; 6(9):e601-e612. PMID: 31498109.
      View in: PubMed
    2. Lehane A, Were M, Wade M, Hamadu M, Cahill M, Kiconco S, Kajubi R, Aweeka F, Mwebaza N, Li F, Parikh S. Comparison on simultaneous caillary and venous parasite density and genotyping results from children and adults with uncomplicated malaria: a prospective observational study in Uganda. BMC Infect Dis. 2019 Jun 26; 19(1):559. PMID: 31242863.
      View in: PubMed
    3. Kardashian A, Ma Y, Yin MT, Scherzer R, Nolan O, Aweeka F, Tien PC, Price JC. High Kynurenine:Tryptophan Ratio Is Associated With Liver Fibrosis in HIV-Monoinfected and HIV/Hepatitis C Virus-Coinfected Women. Open Forum Infect Dis. 2019 Jul; 6(7):ofz281. PMID: 31304190.
      View in: PubMed
    4. Whalen ME, Kajubi R, Chamankhah N, Huang L, Orukan F, Wallender E, Kamya MR, Dorsey G, Jagannathan P, Rosenthal PJ, Mwebaza N, Aweeka FT. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention. Clin Pharmacol Ther. 2019 Jun 07. PMID: 31173649.
      View in: PubMed
    5. Huang L, Cheah V, Chan D, Marzan F, Dvorak CC, Aweeka FT, Long-Boyle J. Determination of melphalan in human plasma by UPLC-UV method. Cancer Chemother Pharmacol. 2019 May; 83(5):905-910. PMID: 30847504.
      View in: PubMed
    6. Wallender E, Zhang N, Conrad M, Kakuru A, Muhindo M, Tumwebaze P, Kajubi R, Mota D, Legac J, Jagannathan P, Havlir D, Kamya M, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda. Antimicrob Agents Chemother. 2019 02; 63(2). PMID: 30530597.
      View in: PubMed
    7. Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P. Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. Antimicrob Agents Chemother. 2018 10; 62(10). PMID: 30038039.
      View in: PubMed
    8. Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis. 2018 09 14; 67(7):1079-1088. PMID: 29547881.
      View in: PubMed
    9. Huang L, Mwebaza N, Kajubi R, Marzan F, Forsman C, Parikh S, Aweeka FT. Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients. PLoS One. 2018; 13(8):e0202082. PMID: 30114201.
      View in: PubMed
    10. Jagannathan P, Kakuru A, Okiring J, Muhindo MK, Natureeba P, Nakalembe M, Opira B, Olwoch P, Nankya F, Ssewanyana I, Tetteh K, Drakeley C, Beeson J, Reiling L, Clark TD, Rodriguez-Barraquer I, Greenhouse B, Wallender E, Aweeka F, Prahl M, Charlebois ED, Feeney ME, Havlir DV, Kamya MR, Dorsey G. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med. 2018 07; 15(7):e1002606. PMID: 30016328.
      View in: PubMed
    11. Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018 06; 15(6):e1002579. PMID: 29894518.
      View in: PubMed
    12. Glennon EKK, Megawati D, Torrevillas BK, Ssewanyana I, Huang L, Aweeka F, Greenhouse B, Adams LG, Luckhart S. Elevated plasma abscisic acid is associated with asymptomatic falciparum malaria and with IgG-/caspase-1-dependent immunity in Plasmodium yoelii-infected mice. Sci Rep. 2018 06 11; 8(1):8896. PMID: 29891920.
      View in: PubMed
    13. Huang L, Haagensen JAJ, Verotta D, Cheah V, Spormann AM, Aweeka F, Yang K. Determination of Tobramycin in M9 Medium by LC-MS/MS: Signal Enhancement by Trichloroacetic Acid. J Anal Methods Chem. 2018; 2018:7965124. PMID: 29854560.
      View in: PubMed
    14. Ippolito MM, Huang L, Siame M, Thuma P, Shapiro TA, Aweeka FT. Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS/MS. J Pharm Biomed Anal. 2018 Jun 05; 155:241-246. PMID: 29655094.
      View in: PubMed
    15. Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis. 2018 03 05; 217(6):964-972. PMID: 29272443.
      View in: PubMed
    16. Jagannathan P, Kajubi R, Aweeka FT. Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction". Clin Pharmacol Ther. 2018 04; 103(4):571. PMID: 29322501.
      View in: PubMed
    17. Conrad MD, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P, Whalen M, Kakuru A, Nayebare P, Wallender E, Havlir DV, Jagannathan P, Huang L, Aweeka F, Kamya MR, Dorsey G, Rosenthal PJ. Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda. J Infect Dis. 2017 11 15; 216(8):1008-1017. PMID: 28968782.
      View in: PubMed
    18. Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L, Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. PLoS One. 2017; 12(10):e0186589. PMID: 29065172.
      View in: PubMed
    19. Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1701-1713. PMID: 28684371.
      View in: PubMed
    20. Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Ruel T, Koss CA, Kakuru A, Mwebaza N, Kamya M, Havlir D, Dorsey G, Rosenthal PJ, Aweeka FT. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther. 2017 Sep; 102(3):520-528. PMID: 28187497.
      View in: PubMed
    21. O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger JS, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F, Aberg JA. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infect Dis. 2017; 4(1):ofw278. PMID: 28480270.
      View in: PubMed
    22. Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, Gingrich D, Nyunt MM, Ssebuliba J, Mwebaza N, Aweeka FT, Parikh S. Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. Open Forum Infect Dis. 2016 Oct; 3(4):ofw217. PMID: 28018925.
      View in: PubMed
    23. Tchaparian E, Sambol NC, Arinaitwe E, McCormack SA, Bigira V, Wanzira H, Muhindo M, Creek DJ, Sukumar N, Blessborn D, Tappero JW, Kakuru A, Bergqvist Y, Aweeka FT, Parikh S. Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. J Infect Dis. 2016 Oct 15; 214(8):1243-51. PMID: 27471317.
      View in: PubMed
    24. Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis. 2016 08 01; 63(3):414-22. PMID: 27143666.
      View in: PubMed
    25. Jagannathan P, Bowen K, Nankya F, McIntyre TI, Auma A, Wamala S, Sikyomu E, Naluwu K, Nalubega M, Boyle MJ, Farrington LA, Bigira V, Kapisi J, Aweeka F, Greenhouse B, Kamya M, Dorsey G, Feeney ME. Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10. J Infect Dis. 2016 07 15; 214(2):329-38. PMID: 27067196.
      View in: PubMed
    26. Weinberg A, Park JG, Bosch R, Cho A, Livingston E, Aweeka F, Cramer Y, Watts DH, Luque AE, Cohn SE. Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):137-45. PMID: 26413850.
      View in: PubMed
    27. Dumond JB, Rigdon J, Mollan K, Tierney C, Kashuba AD, Aweeka F, Collier AC. Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results. J Acquir Immune Defic Syndr. 2015 Dec 15; 70(5):510-4. PMID: 26230332.
      View in: PubMed
    28. Nyunt MM, Nguyen VK, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Mwima MW, Achan J, Aweeka F, Parikh S, Mwebaza N. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1274-82. PMID: 26666942.
      View in: PubMed
    29. Sundell K, Jagannathan P, Huang L, Bigira V, Kapisi J, Kakuru MM, Savic R, Kamya MR, Dorsey G, Aweeka F. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Malar J. 2015 Sep 24; 14:368. PMID: 26403465.
      View in: PubMed
    30. Parikh S, Fehintola F, Huang L, Olson A, Adedeji WA, Darin KM, Morse GD, Murphy RL, Taiwo BO, Akinyinka OO, Adewole IF, Aweeka FT, Scarsi KK. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. Antimicrob Agents Chemother. 2015 Dec; 59(12):7852-6. PMID: 26392500.
      View in: PubMed
    31. Sha BE, Tierney C, Sun X, Stek A, Cohn SE, Coombs RW, Bastow B, Aweeka FT. PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150. Jacobs J AIDS HIV. 2015; 1(1). PMID: 26878071.
      View in: PubMed
    32. Sambol NC, Yan L, Creek DJ, McCormack SA, Arinaitwe E, Bigira V, Wanzira H, Kakuru A, Tappero JW, Lindegardh N, Tarning J, Nosten F, Aweeka FT, Parikh S. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria. Clin Pharmacol Ther. 2015 Jul; 98(1):87-95. PMID: 25732044.
      View in: PubMed
    33. Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 06 15; 60(12):1842-51. PMID: 25767256.
      View in: PubMed
    34. Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Pediatr Infect Dis J. 2015 Mar; 34(3):e63-70. PMID: 25742090.
      View in: PubMed
    35. Luque AE, Cohn SE, Park JG, Cramer Y, Weinberg A, Livingston E, Klingman KL, Aweeka F, Watts DH. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. Antimicrob Agents Chemother. 2015 Apr; 59(4):2094-101. PMID: 25624326.
      View in: PubMed
    36. Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014 Dec 01; 67(4):375-81. PMID: 25162818.
      View in: PubMed
    37. Kamya MR, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Kakuru A, Aweeka FT, Huang L, Jagannathan P, Achan J, Havlir DV, Rosenthal PJ, Dorsey G. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014 Nov 28; 28(18):2701-9. PMID: 25493596.
      View in: PubMed
    38. Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med. 2015 Mar; 16(3):176-83. PMID: 25407158.
      View in: PubMed
    39. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS. Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Ann Intern Med. 2014 Oct 07; 161(7):I-22. PMID: 25285557.
      View in: PubMed
    40. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 07; 161(7):461-71. PMID: 25285539.
      View in: PubMed
    41. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 2014 Aug; 11(8):e1001689. PMID: 25093754.
      View in: PubMed
    42. Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep; 58(9):5245-52. PMID: 24957823.
      View in: PubMed
    43. Huang L, Haagensen J, Verotta D, Lizak P, Aweeka F, Yang K. Determination of meropenem in bacterial media by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15; 961:71-6. PMID: 24861874.
      View in: PubMed
    44. Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 01; 960:194-9. PMID: 24820973.
      View in: PubMed
    45. Scarsi KK, Fehintola FA, Ma Q, Aweeka FT, Darin KM, Morse GD, Akinola IT, Adedeji WA, Lindegardh N, Tarning J, Ojengbede O, Adewole IF, Taiwo B, Murphy RL, Akinyinka OO, Parikh S. Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. J Antimicrob Chemother. 2014 May; 69(5):1370-6. PMID: 24446424.
      View in: PubMed
    46. Kjellin LL, Dorsey G, Rosenthal PJ, Aweeka F, Huang L. Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS. Bioanalysis. 2014; 6(23):3081-9. PMID: 25529877.
      View in: PubMed
    47. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2014 Feb; 54(2):121-32. PMID: 24038035.
      View in: PubMed
    48. Huang L, Lizak P, Aweeka F, Long-Boyle J. Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS. J Pharm Biomed Anal. 2013 Dec; 86:198-203. PMID: 24013121.
      View in: PubMed
    49. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013 Aug 15; 63(5):578-84. PMID: 24135775.
      View in: PubMed
    50. Gruber VA, Rainey PM, Lum PJ, Beatty GW, Aweeka FT, McCance-Katz EF. Interactions between alcohol and the HIV entry inhibitor Maraviroc. J Int Assoc Provid AIDS Care. 2013 Nov-Dec; 12(6):375-7. PMID: 23881910.
      View in: PubMed
    51. Huang L, Olson A, Gingrich D, Aweeka FT. Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method. Bioanalysis. 2013 Jun; 5(12):1501-6. PMID: 23795928.
      View in: PubMed
    52. Liu L, Wang L, Huang L, Siu V, Teque F, Aweeka FT, Levy JA. Nevirapine inhibits the anti-HIV activity of CD8+ cells. J Acquir Immune Defic Syndr. 2013 Jun 01; 63(2):184-8. PMID: 23392464.
      View in: PubMed
    53. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93. PMID: 23592830.
      View in: PubMed
    54. Gwaza L, Aweeka F, Greenblatt R, Lizak P, Huang L, Guglielmo BJ. Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir. Int J Infect Dis. 2013 Oct; 17(10):e857-61. PMID: 23587599.
      View in: PubMed
    55. Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013 Jun; 57(6):2780-7. PMID: 23571542.
      View in: PubMed
    56. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis. 2013 Jun 01; 207(11):1646-54. PMID: 23447696.
      View in: PubMed
    57. Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013 Feb; 56(4):598-605. PMID: 23243180.
      View in: PubMed
    58. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29; 367(22):2110-8. PMID: 23190222.
      View in: PubMed
    59. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):310-6. PMID: 22918158.
      View in: PubMed
    60. Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother. 2012 Oct; 56(10):5374-80. PMID: 22869579.
      View in: PubMed
    61. Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012 Nov; 42(11):1088-95. PMID: 22671777.
      View in: PubMed
    62. Dong BJ, Zheng Y, Hughes MD, Frymoyer A, Verotta D, Lizak P, Sawe F, Currier JS, Lockman S, Aweeka FT. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS. 2012 Apr 24; 26(7):833-41. PMID: 22301417.
      View in: PubMed
    63. Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012 Apr 15; 59(5):455-62. PMID: 22126739.
      View in: PubMed
    64. Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Taiwo B, Akinola IT, Adewole IF, Lindegardh N, Phakderaj A, Ojengbede O, Murphy RL, Akinyinka OO, Aweeka FT. Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS Res Treat. 2012; 2012:703604. PMID: 22500218.
      View in: PubMed
    65. Huang L, Li X, Marzan F, Lizak PS, Aweeka FT. Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis. 2012 Jan; 4(2):157-66. PMID: 22250798.
      View in: PubMed
    66. Sha BE, Tierney C, Cohn SE, Sun X, Coombs RW, Frenkel LM, Kalams SA, Aweeka FT, Bastow B, Bardeguez A, Kmack A, Stek A. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials. 2011 Jan-Feb; 12(1):9-23. PMID: 21388937.
      View in: PubMed
    67. Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010 Dec; 55(4):473-82. PMID: 20842042.
      View in: PubMed
    68. Taylor SA, Lee GA, Pao VY, Anthonypillai J, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr. 2010 Nov; 55(3):361-4. PMID: 20595906.
      View in: PubMed
    69. Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):285-9. PMID: 19890215.
      View in: PubMed
    70. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, Aweeka F, Huang Y, Douek DC, Brenchley JM, Martin JN, Hecht FM, Deeks SG, McCune JM. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010 May 19; 2(32):32ra36. PMID: 20484731.
      View in: PubMed
    71. Huang L, Lizak PS, Jayewardene AL, Marzan F, Lee MN, Aweeka FT. A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study. Anal Chem Insights. 2010 Mar 29; 5:15-23. PMID: 20448843.
      View in: PubMed
    72. Pao VY, Lee GA, Taylor S, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers. AIDS. 2010 Jan 16; 24(2):265-70. PMID: 19890203.
      View in: PubMed
    73. Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010 Apr; 11(4):232-8. PMID: 20002783.
      View in: PubMed
    74. Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, Clark TD, Dorsey G, Lindegardh N, Annerberg A, Rosenthal PJ, Kamya MR, Aweeka F. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother. 2010 Jan; 54(1):52-9. PMID: 19841149.
      View in: PubMed
    75. Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One. 2009 Sep 01; 4(9):e6877. PMID: 19721718.
      View in: PubMed
    76. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):424-9. PMID: 19506482.
      View in: PubMed
    77. Huang L, Jayewardene AL, Li X, Marzan F, Lizak PS, Aweeka FT. Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma. J Pharm Biomed Anal. 2009 Dec 05; 50(5):959-65. PMID: 19646837.
      View in: PubMed
    78. Eron JJ, Park JG, Haubrich R, Aweeka F, Bastow B, Pakes GE, Yu S, Wu H, Richman DD. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother. 2009 Jun; 53(6):2335-41. PMID: 19307363.
      View in: PubMed
    79. Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15; 877(3):285-90. PMID: 19112051.
      View in: PubMed
    80. Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis. 2008 Aug 01; 47(3):421-4. PMID: 18558886.
      View in: PubMed
    81. Venhoff N, Venhoff AC, Jayewardene AL, Aweeka F, Lebrecht D, Walker UA. Pharmacokinetics of zidovudine and lamivudine during oral uridine supplementation with NucleomaxX. J Acquir Immune Defic Syndr. 2008 May 01; 48(1):114-6. PMID: 18438180.
      View in: PubMed
    82. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008 Apr; 9(4):214-20. PMID: 18366444.
      View in: PubMed
    83. German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet. 2008; 47(2):91-102. PMID: 18193915.
      View in: PubMed
    84. Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007 Oct 18; 21(16):2183-90. PMID: 18090045.
      View in: PubMed
    85. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007 Oct 18; 21(16):2191-9. PMID: 18090046.
      View in: PubMed
    86. Aweeka FT, Kang M, Yu JY, Lizak P, Alston B, Chung RT. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Med. 2007 Jul; 8(5):288-94. PMID: 17561874.
      View in: PubMed
    87. German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, Lindegardh N, Havlir D, Aweeka FT. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007 Mar 15; 44(6):889-91. PMID: 17304470.
      View in: PubMed
    88. Aweeka FT, Rosenkranz SL, Segal Y, Coombs RW, Bardeguez A, Thevanayagam L, Lizak P, Aberg J, Watts DH. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS. 2006 Sep 11; 20(14):1833-41. PMID: 16954724.
      View in: PubMed
    89. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006 Sep 01; 43(5):658-60. PMID: 16886163.
      View in: PubMed
    90. McGee B, Smith N, Aweeka F. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials. 2006 May-Jun; 7(3):142-53. PMID: 16880170.
      View in: PubMed
    91. Motoya T, Thevanayagam LN, Blaschke TF, Au S, Stone JA, Jayewardene AL, Chi J, Aweeka FT. Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions. HIV Med. 2006 Mar; 7(2):122-8. PMID: 16420257.
      View in: PubMed
    92. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005 Nov 01; 192(9):1537-44. PMID: 16206068.
      View in: PubMed
    93. Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. HIV Clin Trials. 2005 Sep-Oct; 6(5):246-53. PMID: 16306031.
      View in: PubMed
    94. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11. PMID: 15498605.
      View in: PubMed
    95. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004 Mar 05; 18(4):641-9. PMID: 15090769.
      View in: PubMed
    96. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004; 44:499-523. PMID: 14744256.
      View in: PubMed
    97. Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, Sheiner LB. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther. 2003 Dec; 74(6):569-80. PMID: 14663459.
      View in: PubMed
    98. Floren LC, Wiznia A, Hayashi S, Jayewardene A, Stanley K, Johnson G, Nachman S, Krogstad P, Aweeka FT. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics. 2003 Sep; 112(3 Pt 1):e220-7. PMID: 12949316.
      View in: PubMed
    99. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003 Aug 19; 139(4):258-66. PMID: 12965981.
      View in: PubMed
    100. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS. 2003 May 23; 17(8):1195-9. PMID: 12819521.
      View in: PubMed
    101. Chi J, Jayewardene AL, Stone JA, Aweeka FT. An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. J Pharm Biomed Anal. 2003 Apr 01; 31(5):953-9. PMID: 12684107.
      View in: PubMed
    102. Chi J, Jayewardene AL, Stone JA, Motoya T, Aweeka FT. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. J Pharm Biomed Anal. 2002 Oct 15; 30(3):675-84. PMID: 12367693.
      View in: PubMed
    103. Wohl DA, Aweeka FT, Schmitz J, Pomerantz R, Cherng DW, Spritzler J, Fox L, Simpson D, Bell D, Holohan MK, Thomas S, Robinson W, Kaplan G, Teppler H. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis. 2002 May 01; 185(9):1359-63. PMID: 12001058.
      View in: PubMed
    104. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002 Mar 29; 16(5):F1-8. PMID: 11964551.
      View in: PubMed
    105. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002 Mar 08; 16(4):569-77. PMID: 11873000.
      View in: PubMed
    106. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS. 2002 Mar 08; 16(4):543-50. PMID: 11872997.
      View in: PubMed
    107. Herforth C, Stone JA, Jayewardene AL, Blaschke TF, Fang F, Motoya T, Aweeka FT. Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization. Eur J Pharm Sci. 2002 Mar; 15(2):185-95. PMID: 11849916.
      View in: PubMed
    108. Chi J, Jayewardene A, Stone J, Gambertoglio JG, Aweeka FT. A direct determination of thymidine triphosphate concentrations without dephosphorylation in peripheral blood mononuclear cells by LC/MS/MS. J Pharm Biomed Anal. 2001 Dec; 26(5-6):829-36. PMID: 11600294.
      View in: PubMed
    109. Aweeka F, Trapnell C, Chernoff M, Jayewardene A, Spritzler J, Bellibas SE, Lizak P, Jacobson J. Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. J Clin Pharmacol. 2001 Oct; 41(10):1091-7. PMID: 11583477.
      View in: PubMed
    110. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, Gulick R, Hughes V, Flexner C, Aweeka F, Hsu A, Gal J. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001 Jun 01; 27(2):153-60. PMID: 11404537.
      View in: PubMed
    111. Jayewardene AL, Kearney B, Stone JA, Gambertoglio JG, Aweeka FT. An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma. J Pharm Biomed Anal. 2001 May; 25(2):309-17. PMID: 11275438.
      View in: PubMed
    112. Zhang L, Price R, Aweeka F, Bellibas SE, Sheiner LB. Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study. Eur J Pharm Sci. 2001 Feb; 12(4):377-85. PMID: 11231104.
      View in: PubMed
    113. Tsunoda SM, Aweeka FT. Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. BioDrugs. 2000 Dec; 14(6):355-69. PMID: 18034579.
      View in: PubMed
    114. Homma M, Beckerman K, Hayashi S, Jayewardene AL, Oka K, Gambertoglio JG, Aweeka FT. Liquid chromatographic determination of urinary 6beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women. J Pharm Biomed Anal. 2000 Sep; 23(4):629-35. PMID: 10975239.
      View in: PubMed
    115. Hayashi S, Beckerman K, Homma M, Kosel BW, Aweeka FT. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS. 2000 May 26; 14(8):1061-2. PMID: 10853990.
      View in: PubMed
    116. Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, Turncliff RZ. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol. 2000; 49 Suppl 1:27S-33S. PMID: 10771451.
      View in: PubMed
    117. Kosel BW, Aweeka F. Drug interactions of antiretroviral agents. AIDS Clin Rev. 2000-2001; 193-227. PMID: 10999221.
      View in: PubMed
    118. Homma M, Jayewardene AL, Gambertoglio J, Aweeka F. High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob Agents Chemother. 1999 Nov; 43(11):2716-9. PMID: 10543752.
      View in: PubMed
    119. Kearney BP, Aweeka FT. The penetration of anti-infectives into the central nervous system. Neurol Clin. 1999 Nov; 17(4):883-900. PMID: 10517933.
      View in: PubMed
    120. Hayashi S, Jayesekera D, Jayewardene A, Shah A, Thevanayagam L, Aweeka F. Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. J Clin Pharmacol. 1999 Oct; 39(10):1085-93. PMID: 10516944.
      View in: PubMed
    121. Jayasekara D, Aweeka FT, Rodriguez R, Kalayjian RC, Humphreys MH, Gambertoglio JG. Antiviral therapy for HIV patients with renal insufficiency. J Acquir Immune Defic Syndr. 1999 Aug 15; 21(5):384-95. PMID: 10458619.
      View in: PubMed
    122. Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999 Jun 18; 13(9):1051-61. PMID: 10397535.
      View in: PubMed
    123. Aweeka FT, Gottwald MD, Gambertoglio JG, Wright TL, Boyer TD, Pollock AS, Eldon MA, Kugler AR, Alldredge BK. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia. 1999 Jun; 40(6):777-82. PMID: 10368078.
      View in: PubMed
    124. Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, Tsunoda S, Gambertoglio JG. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 01; 20(4):350-7. PMID: 10096579.
      View in: PubMed
    125. Aweeka F, Jayewardene A, Staprans S, Bellibas SE, Kearney B, Lizak P, Novakovic-Agopian T, Price RW. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 01; 20(1):39-43. PMID: 9928728.
      View in: PubMed
    126. Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther. 1999 Jan; 65(1):21-8. PMID: 9951427.
      View in: PubMed
    127. Jayewardene AL, Zhu F, Aweeka FT, Gambertoglio JG. Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J Chromatogr B Biomed Sci Appl. 1998 Apr 10; 707(1-2):203-11. PMID: 9613951.
      View in: PubMed
    128. Aweeka FT, Brody SR, Jacobson M, Botwin K, Martin-Munley S. Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration? Clin Ther. 1998 Mar-Apr; 20(2):232-43. PMID: 9589815.
      View in: PubMed
    129. Brody SR, Aweeka FT. Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model. Int J Antimicrob Agents. 1997 Sep; 9(2):131-5. PMID: 18611830.
      View in: PubMed
    130. Wolfe EJ, Mathur V, Tomlanovich S, Jung D, Wong R, Griffy K, Aweeka FT. Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy. 1997 May-Jun; 17(3):591-8. PMID: 9165564.
      View in: PubMed
    131. Aweeka FT, Kwong M, Mak M, al-Uzri A, Affrime M, Cutler D, Kahn J, Gambertoglio JG. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine. J Clin Pharmacol. 1996 Dec; 36(12):1107-13. PMID: 9013366.
      View in: PubMed
    132. Alexander AC, Akers A, Matzke GR, Aweeka FT, Fraley DS. Disposition of foscarnet during peritoneal dialysis. Ann Pharmacother. 1996 Oct; 30(10):1106-9. PMID: 8893116.
      View in: PubMed
    133. Drusano GL, Aweeka F, Gambertoglio J, Jacobson M, Polis M, Lane HC, Eaton C, Martin-Munley S. Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients. AIDS. 1996 Sep; 10(10):1113-9. PMID: 8874628.
      View in: PubMed
    134. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet. 1996 Feb; 30(2):107-40. PMID: 8906895.
      View in: PubMed
    135. d'Uscio CH, Aweeka FT, Prueksaritanont T, Tomlanovich SJ, Gupta SK, Lantz MV, Gambertoglio JG, Garovoy MR, Benet LZ. Immunopharmacodynamic studies of cyclosporine in patients awaiting renal transplantation. J Clin Pharmacol. 1995 Oct; 35(10):967-73. PMID: 8568014.
      View in: PubMed
    136. Aweeka FT, Mak M, al-Uzri A, Peter K, Dett C, Franco J, Affrime M, Guerciolini R, Cutler DL, Kahn J. Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. J Clin Pharmacol. 1995 Sep; 35(9):856-64. PMID: 8786245.
      View in: PubMed
    137. Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, Jacobson MA. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. Clin Pharmacol Ther. 1995 Apr; 57(4):403-12. PMID: 7712668.
      View in: PubMed
    138. Aweeka FT, Tomlanovich SJ, Prueksaritanont T, Gupta SK, Benet LZ. Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. J Clin Pharmacol. 1994 Jan; 34(1):60-7. PMID: 8132853.
      View in: PubMed
    139. Aweeka FT, Gambertoglio JG, van der Horst C, Raasch R, Jacobson MA. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). Antimicrob Agents Chemother. 1992 Aug; 36(8):1773-8. PMID: 1416864.
      View in: PubMed
    140. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab. 1991 May; 72(5):1130-5. PMID: 1827127.
      View in: PubMed
    141. Hassanzadeh MK, Aweeka FT, Wu S, Jacobson MA, Gambertoglio JG. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1990 Jan 26; 525(1):133-40. PMID: 2140113.
      View in: PubMed
    142. Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989 May; 33(5):742-5. PMID: 2546491.
      View in: PubMed
    143. Aweeka F, Lizak P, Garovoy M, Amend W, Birnbaum J, Gumbert M, Gambertoglio J. Interleukin-2 and immunoglobulin increases with H2-antagonists in humans. Transplant Proc. 1989 Feb; 21(1 Pt 2):1718-21. PMID: 2523589.
      View in: PubMed
    144. Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct; 158(4):862-5. PMID: 2844921.
      View in: PubMed